Novavax Inc
NVAX
Key stats
- Open
- 9.70
- Day high
- 9.74
- Day low
- 8.75
- Previous close
- 9.98
- Volume
- 7.01M
- VWAP
- 9.15
- 52-week high
- 13.39
- 52-week low
- 6.20
- Market cap
- 1.65B
- Shares out
- 164.95M
- Employees
- 749
- Listed
- 1995
About Novavax Inc
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · GAITHERSBURG, MD · novavax.com
Options · expiring Nov 13
Nov 12, 4:00 PM ET- Call open interest
- 4.1K
- Put open interest
- 1.6K
- Put/call
- 0.39
- At-the-money IV
- 106.8%
| Contract | Last | Traded | Volume | Open int. | IV |
|---|---|---|---|---|---|
| 9.50 call | 0.05 | Nov 12, 3:29 PM | 501 | 124 | 209.6% |
| 9 put | 0.25 | Nov 12, 3:48 PM | 270 | 134 | 81.5% |
| 9.50 put | 0.80 | Nov 12, 3:57 PM | 173 | 166 | — |
| 10 call | 0.02 | Nov 12, 2:18 PM | 101 | 299 | 172.3% |
| 9 call | 0.13 | Nov 12, 3:57 PM | 73 | 118 | 106.8% |
| 11 call | 0.02 | Nov 12, 2:51 PM | 29 | 3.3K | 273.3% |
Quarterly results
Massive · Nov 5, 2026| Q3 2026 to Sep 30, 2026 | Q2 2026 to Jun 30, 2026 | Q1 2026 to Mar 31, 2026 | Q4 2025 to Dec 31, 2025 | |
|---|---|---|---|---|
| Revenue | $68.30M | $56.70M | $139.51M | $147.14M |
| Gross profit | $44.81M | $42.45M | $108.82M | $125.03M |
| Operating income | −$31.28M | −$54.91M | −$15.43M | $14.23M |
| Net income | −$31.38M | −$53.39M | −$9.49M | $17.53M |
| Diluted EPS | -0.19 | -0.32 | -0.06 | 0.10 |
| Operating cash flow | −$94.24M | −$72.81M | −$32.42M | −$39.48M |
| Assets | $888.00M | $955.58M | $1.04B | $1.18B |
| Liabilities | $1.10B | $1.15B | $1.19B | $1.30B |
| Equity | −$216.85M | −$190.71M | −$144.76M | −$127.75M |
Technicals
Massive · Nov 12, 2026- 50-day average10.57
- 200-day average9.34
- RSI (14 days)38.9
Short interest
Massive · Oct 30, 2026- Oct 30, 202646.33M shares · 7.6 days to cover
- Oct 15, 202647.35M shares · 4.3 days to cover
- Sep 30, 202646.05M shares · 8.1 days to cover
- Sep 15, 202649.88M shares · 9.3 days to cover
Dividends
Massive · Dec 13, 2007- Ex Dec 13, 2007, paid Dec 31, 20070.1063 · 12 a year
- Ex Nov 13, 2007, paid Nov 30, 20070.1063 · 12 a year
- Ex Oct 11, 2007, paid Oct 31, 20070.1063 · 12 a year
- Ex Sep 13, 2007, paid Sep 28, 20070.1063 · 12 a year
- Ex Aug 13, 2007, paid Aug 31, 20070.1063 · 12 a year
- Ex Jul 12, 2007, paid Jul 31, 20070.1063 · 12 a year
Splits
Massive · May 10, 2019- May 10, 20191-for-20
Related companies
MassiveNews coverage
No stories about Novavax Inc right now.